Content Status
Type
Linked Node
Preventive Treatment for Contacts of DR-TB Patients: WHO Recommendations
Learning ObjectivesPreventive Treatment for Contacts of DR-TB Patients: WHO Recommendations
The World Health Organisation (WHO) recommends Tuberculosis Preventive Treatment (TPT) among contacts exposed to Multidrug-resistant TB (MDR-TB) with Fluoroquinolone (FQ)-sensitive, or Isoniazid (H)-resistant with Rifampicin (R) sensitive DR-TB patients.
Points to be Considered Before TPT Initiation
- The preventive treatment should be individualized after a careful assessment of the intensity of exposure of contact with the index case.
- Confirm the source patient and her/his drug resistance pattern bacteriologically.
- Ascertain Latent TB Infection (LTBI) using Interferon Gamma Release Assay (IGRA) or Tuberculin Skin Tests (TST).
|
TPT REGIMEN |
ELIGIBLE POPULATION |
|---|---|
|
6Lfx (six-month Levofloxacin) |
Among contacts exposed to patients with known MDR and FQ-sensitive TB |
|
6H (six-month Isoniazid) |
Among contacts of H-susceptible TB in confirmed R-resistant TB index patient |
|
4R (four-month Rifampicin) |
Among contacts with known H-resistant and R-sensitive TB |
Regardless of whether treatment is given or not, clinical follow-up should be done for two years.
Any emergent signs and symptoms suggestive of TB should be actively investigated and curative regimens started, as needed.
Resources
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
- Consolidated Guidelines on Tuberculosis: Module 1: Prevention: Tuberculosis Preventive Treatment, 2020.
- Latent TB Infection: Updated and Consolidated Guidelines for Programmatic Management, WHO, 2018.
Kindly provide your valuable feedback on the page to the link provided HERE
Content Creator
Reviewer
Target Audience
- Log in to post comments